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Abstract
Background: Vaccine protection investigation includes three processes: vaccination, pathogen challenge, and
vaccine protection efficacy assessment. Many variables can affect the results of vaccine protection. Brucella, a genus
of facultative intracellular bacteria, is the etiologic agent of brucellosis in humans and multiple animal species.
Extensive research has been conducted in developing effective live attenuated Brucella vaccines. We hypothesized
that some variables play a more important role than others in determining vaccine protective efficacy. Using
Brucella vaccines and vaccine candidates as study models, this hypothesis was tested by meta-analysis of Brucella
vaccine studies reported in the literature.
Results: Nineteen variables related to vaccine-induced protection of mice against infection with virulent brucellae
were selected based on modeling investigation of the vaccine protection processes. The variable “vaccine
protection efficacy” was set as a dependent variable while the other eighteen were set as independent variables.
Discrete or continuous values were collected from papers for each variable of each data set. In total, 401
experimental groups were manually annotated from 74 peer-reviewed publications containing mouse protection
data for live attenuated Brucella vaccines or vaccine candidates. Our ANOVA analysis indicated that nine variables
contributed significantly (P-value < 0.05) to Brucella vaccine protection efficacy: vaccine strain, vaccination host
(mouse) strain, vaccination dose, vaccination route, challenge pathogen strain, challenge route, challenge-killing
interval, colony forming units (CFUs) in mouse spleen, and CFU reduction compared to control group. The other
10 variables (e.g., mouse age, vaccination-challenge interval, and challenge dose) were not found to be statistically
significant (P-value > 0.05). The protection level of RB51 was sacrificed when the values of several variables (e.g.,
vaccination route, vaccine viability, and challenge pathogen strain) change. It is suggestive that it is difficult to
protect against aerosol challenge. Somewhat counter-intuitively, our results indicate that intraperitoneal and
subcutaneous vaccinations are much more effective to protect against aerosol Brucella challenge than intranasal
vaccination.
Conclusions: Literature meta-analysis identified variables that significantly contribute to Brucella vaccine protection
efficacy. The results obtained provide critical information for rational vaccine study design. Literature meta-analysis
is generic and can be applied to analyze variables critical for vaccine protection against other infectious diseases.
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Background
Bioinformatics meta-analysis has become an important
tool in the analysis of biomedical literature. The term
“meta-analysis” was coined by Glass in the 1970s to
describe the process of gathering and combining infor-
mation from many studies of the same type [1]. As a
quantitative and systematic process, meta-analysis is
able to derive overarching conclusions about a specific
area of research. Outcomes from a pooled meta-analysis
may include a more precise estimate of the effect of bio-
logical factors or outcomes than could be obtained from
an individual study. Meta-analysis has the substantial
benefit of investigating new hypotheses using existing
data [2]. Meta-analysis started to make an impact on
medicine in the late 1980s [2,3]. Today, meta-analysis is
frequently applied to examine a wide array of different
biomedical research areas.
Brucella is a genus of facultative intracellular bacteria
that are the etiologic agents of brucellosis in humans and
many animal species. Brucellosis is the most commonly
acquired zoonotic disease, with over half a million new
human cases annually worldwide [4]. Vaccination is one
of the most effective means to protect humans and ani-
mals against brucellosis and other infectious diseases [5].
Although antibodies specific for the O polysaccharide of
Brucella cell wall lipopolysaccharide confer a certain
level of protection in some host species, cell-mediated
immunity is believed to play a critical role in protection
against virulent Brucella infection [6]. As a result, live
attenuated Brucella vaccines, including RB51 and strain
19 (S19), are superior to many other Brucella vaccine
candidates as they tend to induce better cell-mediated
immunity. The superior immunogenicity provided by live
attenuated vaccines is due to their induction of a self-lim-
iting and subclinical condition that simulates natural
infection by virulent pathogens (usually with the same
cell invasion and tissue tropism) and efficiently presents
a full complement of immunogens [7]. Currently, only
cattle brucellosis vaccines (RB51 or S19) are being used
in most countries including the United States and most
of Europe. However, safe and effective Brucella vaccines
are desired for use in humans and many other animal
species (e.g., goats, sheep, pigs, and wildlife). As a result,
much research has been conducted and published in the
area of Brucella vaccine research and development.
The mouse is the primary mammalian model used in
the study of vaccine candidates including those against
Brucella species [8]. Mice are genetically similar to
humans with similar immune defenses and physiological
mechanisms. The mouse genome sequence is available
and has been well studied compared to other animal mod-
els. One critical issue to consider with vaccine animal stu-
dies is that many variables (e.g., vaccine doses, vaccination
routes, and mouse strains and ages) can affect the
outcomes of vaccine protection assays. A vaccine candi-
date may be concluded to be protective in a mouse study;
however, using a different experimental protocol, the same
vaccine candidate may be not protective anymore.
Scientists often rely on previous research reports when
formulating the experimental design for a future vaccine
protection study. However, the large amount of literature
reports often provides a variety of choices for setting
the values of different variables. Sometimes conflicting
results are found, causing confusion. It is frequently a
challenge to design an experiment with optimal settings
for different variables.
A vaccine protection investigation includes three pro-
cesses: vaccination, pathogen challenge, and vaccine pro-
tection efficacy assessment [9]. A diverse assortment of
variables may affect the results of vaccine protection. We
hypothesize that some experimental variables play more
important roles than others in determining the protection
efficacy of any specific type of vaccines. In the Special
Interest Group (SIG) meeting of “Bio-Ontologies 2010:
Semantic Applications in Life Sciences” at the 18th annual
conference on Intelligent Systems for Molecular Biology
(ISMB 2010), we reported a preliminary study of an onto-
logical representation of these variables using the Vaccine
Ontology (VO) [10-12] and the Ontology for Biomedical
Investigations (OBI) [13]. This ontological representation
of statistical ANOVA analysis was used to analyze Brucella
vaccine protections. In total, 151 mouse groups of Brucella
vaccine protection investigations were collected from the
literature and used to analyze 16 variables through
ANOVA analysis. However, the focus of this study was on
ontological representation of ANOVA statistical analysis
instead of detailed meta-analysis of the vaccine protection
studies. In addition, some of the relevant data in
the domain of Brucella vaccine protection studies were
not annotated. Whole-organism vaccines are generated
based on whole organisms [14]. Two basic types of whole-
organism vaccines exist. Live attenuated organisms are
usually genetically generated through defined or undefined
gene mutations of a wild type pathogen or by using close
relatives to the target pathogen. Live vaccines cause a sub-
clinical infection but still induce a protective immune
response in the recipient. The other type of whole-organ-
ism vaccines is based on inactivation of whole intact
organisms through high temperature (heating), chemical
treatment, or physical treatment (e.g., gamma irradiation).
The immunogenicity of nonliving whole-organism vac-
cines can be enhanced using vaccine adjuvants [15]. In
this study, we focus on meta-analysis of mouse protection
studies of whole-organism Brucella vaccines and vaccine
candidates. To obtain the most valuable conclusions, all
available literature data in this domain were annotated. A
detailed statistical analysis was performed for each vari-
able. Our meta-analysis provides results that facilitate
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Through review of the available literature, it was noted
that the experimental design for testing vaccine efficacies
varied for different pathogens and in different animal
models. The mouse survival assay is one approach that
measures the death of vaccinated or non-vaccinated mice
after exposure to a virulent pathogen (e.g., virulent influ-
enza, which can kill mice). In these studies, a vaccine’s effi-
cacy is judged by comparing the number of mouse deaths
in the vaccinated and non-vaccinated groups [8]. However,
some virulent pathogens do not kill mice but do colonize
certain organs. In such cases, the colonization or survival
of virulent pathogens in certain target organs (e.g., colon,
spleen, liver, and lung) may be reduced in vaccinated
mice. Accordingly, the colony or plaque forming units
(CFU or PFU) reduction assay can be performed by using
samples extracted from specific tissues. Virulent Brucella
does not kill mice, instead surviving and replicating in the
spleen and liver. Therefore, for Brucella vaccine studies, a
CFU reduction assay in mice has been developed to mea-
sure vaccine effectiveness in mouse models. This Brucella
CFU reduction assay also closely mirrors the normal dis-
ease course in humans and naturally infected animals. As
an example, Brucella abortus cattle vaccine RB51 was
used in a typical vaccine protection study as reported in
reference [16]. In this study, BALB/c mice were vaccinated
with live RB51 (1 × 108 CFU). Eight weeks later, vacci-
nated mice were challenged with virulent B. abortus strain
2308 (1 × 105 CFU). The CFU reduction in vaccinated
mouse spleens was then counted and compared with
those from non-vaccinated mice to determine vaccine pro-
tection [16].
Similar studies were used to generate the data used in
this meta-analysis. A list of variables was first preselected
based on a systematic analysis of the vaccine protection
studies. We have previously reported an ontological
representation of many variables that exist during vaccine
protection investigation [13]. From that preliminary
study, we generated a simple but concise ontological
representation showing how 20 variables were chosen
based on the process pipeline of a typical Brucella vac-
cine protection investigation study (Figure 1). Four vari-
ables are associated with the host, i.e., mouse: Mouse
strain, Mouse sex, Mouse age at the time of vaccination,
and Mouse Sample Size. Five variables are related to
the vaccine used for vaccination: Vaccine strain, Vaccine
viability, Antigen overexpression in live Brucella strain
carrier, Gene mutation, and Vaccine adjuvant. Three
variables are related to the vaccination process: Vaccine
dosage, Vaccination route, and Vaccination frequency.
The variable Vaccination-challenge interval links the
vaccination process with the challenge process. Three
more variables, Challenge route, Challenge Brucella
strain, Challenge dose, and Challenge-killing interval are
associated with the challenge process. All these 17 vari-
ables are independent variables since their values can be
manipulated or changed. With these independent vari-
ables established, three dependent variables can be mea-
sured and evaluated: the CFUs in spleen, CFU reduction,
and the Protection significance level. The results of these
dependent variables are the observed results of the inde-
pendent variables being manipulated. It is noted that the
significance of vaccine protection has two possible values:
“protection” and “no protection”. The assignment of the
value depends on the statistical analysis obtained from
the literature. Specifically, when a statistically significant
result was achieved in a vaccine protection study group
and was clearly described in a peer-reviewed paper, we
assigned “protection” to this study group. Otherwise, “no
protection” was assigned.
Brucella-related vaccinology is an active research area
with more than 1300 peer-reviewed papers stored in
PubMed. In this study, we chose to study only mouse
protection data associated with whole-organism Brucella
vaccines or vaccine candidates. This category includes
live attenuated or inactivated vaccines or vaccine candi-
dates. The inactivation can be generated by heat, chemi-
cals, or gamma-irradiation. This decision avoids the
issue of what to do with vaccine-related variables with
no assignable value (e.g., Vaccine strain for a subunit
vaccine). We have limited our focus to the mouse
model for the following reasons: 1) most Brucella vac-
cine protection studies have been performed using the
mouse model thereby resulting in a large body of avail-
able data, 2) while other animals models (e.g., rats, gui-
nea pigs, and monkeys) have been used [17], the
inclusion of the relatively small amount of data available
for these models would increase the complexity of this
meta-analysis, and 3) by focusing on a small specific
research domain, we can spend a reasonable time to
ensure an inclusion of all possible literature data. Over
100 publications investigated the vaccine protection effi-
cacy of whole-organism Brucella vaccines in the mouse
model. All these papers were annotated. Some papers
were not used for various reasons, for example, lack of
published values for one or more of the 20 variables.
Eventually, 74 papers were included in our study, which
contained complete and relevant experimental data for
our meta-analysis. In total, data of 401 experimental
mouse groups were manually annotated from these
peer-reviewed publications. Each group of mice in a
Brucella vaccine protection study reported in a peer-
reviewed publication is considered as one experimental
dataset.
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With the experimental design and the collected data, a
meta-analysis was performed. The raw data were first
normalized by transformation. The normalized data was
then analyzed by statistical methods including ANOVA.
Our study indicates that many variables contribute to
Brucella vaccine protection, while many do not.
ANOVA statistics analysis identified variables contributing
significantly to the final vaccine protection results
The data transformation procedure is described in the
Methods section. The raw data and normalized data are
provided in Additional file 1. The paper references used
for the data collection are provided in Additional file 2.
To analyze which variables contribute to the vaccine
protection, the significance of vaccine protection is set
as a dependent variable, and the other 18 variables are
independent variables. An ANOVA analysis was per-
formed and indicated that eight parameters significantly
contribute to the vaccine protection (p-value < 0.05)
(Table 1). These eight variables are: CFU reduction,
Challenge route, Vaccine dosage, Vaccine strain, Vacci-
nation route, Mouse strain, Vaccination frequency, and
Challenge Brucella strain. The other 11 variables do not
significantly contribute to the protection (p-value >
0.05).
Nine variables significantly contribute to Brucella
vaccine protection
Each of the nine variables contributed significantly (P-
value < 0.05) to Brucella vaccine protection. Each of these
variables is examined here:
Variable 1: Vaccine strain
The variable “Vaccine strain” covers 17 different vaccine
strains and one saline control (Figure 2). In every experi-
mental study, saline (or PBS buffer) administration was
always used as a negative control. These control groups
never induced any protection. In our meta-analysis study,
we did not include any saline injection experimental
groups in our data analysis. However, the saline control
has been used in every single experimental group study,
since the CFUs in the control group were always used to
calculate the values for the variable CFU reduction for
each treatment group. Among the 17 vaccine strains, an
immunization with nine strains, such as H38, RB51leuB,
recombinant RB51leuB strains expressing protective
Brucella antigens, B. neotomae strain 5K33, and B. suis
2579 mutant (e.g., VTRS1), always generated significant
protection in our record. The other eight vaccine strains
did not induce significant protection in many studies. For
example, B. abortus strains RB51 and S19 are two vaccine
strains that have been used most frequently in various
mouse vaccine protection studies. While both are effec-
tive vaccines, neither of them induced significant protec-
tion in all studies. Among all 165 RB51 experimental
groups, 129 groups (78%) showed statistically significant
protection. For the insignificance of RB51 in inducing
protective immunity in mice, the use of different variable
settings is the main reason:
a) Vaccination route: Oral (PO) vaccination with
RB51 is less effective than intraperitoneal (IP) vacci-
nation [18]. The reduced vaccine efficacy is probably
Figure 1 Ontological representation of a vaccine protection assay and related variables. The variables inside boxes are ontology terms
primarily from the Vaccine Ontology (VO). The italicized relation terms are the terms from the Relation Ontology (RO) and the Ontology for
Biomedical Investigations (OBI).
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Table 1 ANOVA results of 19 variables contributing to Brucella vaccine protection efficacy
# Variables Df Sum Square Mean Square F value P-value (>F)
Variables with statistically significant contribution to protection (P-value < 0.05)
1 CFU Reduction 1 4.32 4.32 58.66 1.574E-13
2 Pathogen challenge route 1 2.20 2.20 29.90 8.278E-08
3 Vaccine dose 1 1.77 1.77 24.09 1.369E-06
4 CFU in spleen 1 0.92 0.92 12.49 4.591E-04
5 Challenge Pathogen Strain 1 0.85 0.85 11.54 0.0008
6 Mouse strain 1 0.58 0.58 7.86 0.0053
7 Vaccine strain 1 0.41 0.41 5.56 0.0188
8 Vaccination route 1 0.41 0.41 5.54 0.0190
9 Challenge-killing Interval 1 0.38 0.38 5.19 0.0232
Variables without statistically significant contribution to protection (P-value > 0.05)
10 Vaccination Frequency 1 0.27 0.27 3.61 0.0581
11 Adjuvant 1 0.18 0.18 2.41 0.1215
12 Vaccination Challenge Interval 1 0.16 0.16 2.20 0.1385
13 Gene Mutation 1 0.12 0.12 1.68 0.1951
14 Mouse Age at Vaccination 1 0.07 0.07 0.97 0.3244
15 Sample Size 1 0.03 0.03 0.47 0.4928
16 Vaccine viability 1 0.02 0.02 0.34 0.5612
17 Antigen Overexpression 1 0.02 0.02 0.23 0.6299
18 Mouse Sex 1 0.01 0.01 0.10 0.7499
19 Challenge Dose 1 0.00 0.00 0.07 0.7988
Note: Nine variables were found to play a significant role (P-value < 0.05), and 10 variables were found not. Df: degree of freedom.
Figure 2 The effect of vaccine strains on induction of protection in mice. Total: all experimental groups are included; Protective: only those
experimental groups showing protective results are included.
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due to the lower persistence of RB51 in vivo after
PO vaccination with RB51 [18]. It was found that
intranasal (IN) vaccination with RB51 did not induce
respiratory protection against intranasal pathogenic
Brucella infection, even when a booster vaccination
step was implemented [19]. However, another study
found that oral administration of RB51 induced pro-
tection to mice orally infected with the virulent B.
abortus strain 2308, but not to mice infected intra-
peritoneally [20].
b) Vaccine viability: Killed RB51 does not seem to
induce immunity in inoculated mice [21,22]. Even
the addition of an IL-12 vaccine adjuvant does not
influence protection induced by vaccination with
killed RB51 [23,24].
c) Challenge route: Mice vaccinated with RB51 and
aerosol challenged with virulent B. abortus strain
S2308 did not show a significant decrease in CFU in
the spleen, liver, or the lungs compared to control
mice [25].
d) Challenge pathogen strain: When virulent
B. melitensis strain 16M was used for mice challenge,
RB51 was not effective in some of the time to protect
RB51-vaccinated mice [26]. RB51 could not protect
mice against virulent B. suis challenge. It is like that
RB51 is a B. abortus vaccine only, and cannot provide
sufficient cross protection against virulent B. meliten-
sis or B. suis infections. However, a recombinant
RB51leuB strain that overexpresses genes encoding
Cu/Zn superoxide dismutase (SOD) and glycosyl-
transferase (WboA) was effective in inducing protec-
tion in mice against infection with virulent B. suis
[27].
Similar to RB51, IN administration of B. abortus vac-
cine strain 19 did not induce significant clearance of
strain 2308 from spleen upon IN challenge infection
compared to the control group [19]. Interestingly, this
failure of S19 inducing significant protection in this case
was the only report that demonstrated the insignificance
of S19 in protection among all 77 experimental groups.
Variable 2: Mouse strain
Seven different types of mouse strains have been used in
Brucella vaccine protection studies: BALB/c, CD1, mixed/
outbred, C57BL/6, OF1, 129/Sv, and Swiss Albino. The
BALB/c mouse model is the most frequently used and has
been used in 294 groups, with 254 groups showing protec-
tion in mice. CD1 is the secondly most frequently used
mouse model, with a total of 70 groups used and 67 of
them inducing protection. It is interesting that the BALB/
c mice immunized with RB51 or S19 appear to reduced
CFU and provide protection against challenge strain
S2308 similar to CD1 mice immunized with RB51 or S19
(Figure 3A and 3B). One possible reason is that compared
to outbred CD1 mice, inbred BALB/c mice are more sen-
sitive to virulent S2308 infection. However, the general
patterns of CFU reduction in RB51 or S19 in both mice
types are similar. RB51-immunized mice induced approxi-
mately 1-1.5 log difference of CFU in the spleen in either
mouse model. S19 induced 2-3 log CFU reduction in
either mouse model (Figure 3C).
Variable 3 and 4: Vaccination route vs. pathogen
challenge route
Vaccination route and challenge route are two important
variables for determining vaccine protection efficacy
results. Among all vaccination routes used, the IP injection
is the most common for Brucella vaccine protection stu-
dies (Figure 4A). Among all 223 experimental groups
using IP vaccination, 205 groups induced significant pro-
tection. All studies with IM (intramuscular), IG (intragas-
tric), and ID (intradermal) vaccination route induced
protection. Most of SC (subcutaneous) and intravenous
(IV) immunizations were successful in induction of pro-
tective immunity. No significant protection results in
mouse spleen were found from the IN immunization
route in all 12 experimental groups, indicating it is prob-
ably difficult to induce protection through IN immuniza-
tion. For example, IN vaccination of mice with either
RB51 or S19 was not able to induce significant clearance
of virulent S2308 infection in spleen compared to saline
control [19]. However, using IN vaccination, S19 (but not
RB51) induced significant clearance of virulent S2308 in
lung against IN challenge with virulent S2308 [19], indicat-
ing that S19 is more effective than RB51 in inducing
respiratory protection. Oral (PO) vaccination appears not
to be a favorable method in inducing protective immunity,
with only 50% of chance of inducing protection. Therefore,
the route of vaccination is an important variable to deter-
mine the protection efficacy even for those known
Brucella vaccines (e.g., RB51).
Similarly, for virulent pathogen challenge, IP was by far
the most used route. Among 271 groups using IP patho-
gen challenge protocol, 256 groups (94.4%) showed pro-
tection (Figure 4B). This rate is considered high. It appears
extremely hard to induce protection against an aerosol
challenge. Only 9 out of 33 groups (27.3%) using aerosol
pathogen challenge induced significant protection. Among
the 9 groups, all of them were achieved by IP vaccination
with B. abortus or B. melitensis mutant strains, such as
BAΔasp24 or BMΔasp24 unmarked mutant strain [28].
The other group that achieved protection against lung
infection is through the IN vaccination with S19 as
described in the above paragraph [19].
Variable 5: Vaccine dose
A large spread of values of vaccine dosage was observed,
ranging from a CFU of 29 (1.46 log) to a CFU of 2 × 1010
(10.3 log) (Additional file 1). The values of doses between
different vaccines may differ dramatically. For example, a
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value of 0.5-5 × 108 CFUs of RB51 is typically used for
RB51 protection study in mice [16,24]. However, the
typical vaccination dose for S19 is 105 [29]. For any single
vaccine, a larger dosage of vaccine induces better
protective immunity. For example, mice are protected
against IN challenge with virulent B. melitensis 16M fol-
lowing oral vaccination with B. melitensis WR201 at a
dose of 1010 or 1011 CFU. The protection level with a
Figure 3 The effects of vaccine strain and mouse strain on vaccine protection (A), CFUs (B), and CFU reduction (C) in mice.
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dose of 1011 CFU is slightly better than that with a
dosage of 1010. However, a dosage of 109 failed to provide
a statistically significant protection [30].
Variable 6: Challenge strain
In total 17 Brucella strains have been used for the 401
groups of Brucella vaccine protection studies. Among
them, B. abortus strain 2308 was used in 184 groups of
mouse studies, with 153 studies generating significant
protection. B. abortus strain S544 is the second most
frequently used strain for mouse challenge. B. melitensis
strain 16M was used in 52 groups.
Variable 7: Challenge-killing interval
This variable represents the time between a pathogen
challenge and mouse killing for CFU measurement. The
Figure 4 The effects of vaccination route (A) and challenge route (B) on induction of protection in mice.
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interval varies a lot in different studies, ranging from
three days to 56 days. One to four weeks are most fre-
quently used challenge-killing interval range. Among
them, the most frequently used challenge-killing interval
is the 14 day, which has been used in 199 experimental
group studies. Thirty-nine of these studies did not gen-
erate protective results.
Variables 8 and 9: CFU vs. CFU reduction
The colony forming unit (CFU) of Brucella in spleen
measures the number of live Brucella cells in a mouse
spleen. Although lung and liver have also been tested,
spleen is the most frequently used organ for CFU test-
ing. The calculation of statistical significance of vaccine-
induced protection in mice is typically performed by a
t-test of comparing the CFUs of spleens between the
treatment group and the control (saline or PBS) group.
The CFU reduction represents the relative reduction of
CFU from treated group compared to the control group,
statistically determines the protection level. Since the
CFU counts may change depending on many variables
such as the mouse type and the dosage of pathogen chal-
lenge, the CFU reduction is considered as a better indica-
tor of the statistical significance of protection than CFU
alone. Our analysis confirms this hypothesis. The CFU
reduction has much more significant P-value than the
CFU variable (Table 1).
Ten variables do not significantly contribute to Brucella
vaccine protection
Ten variables do not significantly contribute to Brucella
vaccine protection (P-value > 0.05). Each of them is
examined below in detail.
(1) Antigen overexpression
Very few vaccines recorded in our study included an over-
expressed Brucella antigen. B. abortus vaccine RB51 is
able to overexpress homologous Brucella proteins as a
way to enhance its vaccine efficacy [31,32]. RB51 has been
used to overexpress Cu/Zn superoxide dismutase (SOD)
[31] and express Brucella glycosyl-transferase (WboA) [33]
to achieved enhanced vaccine efficacy. RB51leuB is an
unmarked leuB mutant of RB51 [34]. The leuB gene,
encoding isopropyl malate dehydrogenase, is essential for
the biosynthesis of leucine in B. abortus. The resultant
leuB auxotroph cannot grow in leucine-deficient condi-
tions. Complementation of the leuB auxotroph with a
plasmid carrying the wild-type leuB gene allows its survi-
val in leucine-deficient minimal medium and under nutri-
ent-limiting conditions in vivo. The selective growth
pressure provides a mechanism for the maintenance of the
plasmid. The environmentally safe leucine auxotroph of
strain RB51 was used to over-express genes encoding
homologous proteins: L7/L12 ribosomal protein, Cu/Zn
superoxide dismutase (SOD) and glycosyl-transferase
(WboA). Mice vaccinated with RB51leuB/SOD/WboA
were significantly better protected than those that were
vaccinated with either strain RB51leuB/SOD or RB51leuB/
SOD/L7/L12 [27]. It was also recently found that non-
pathogenic B. neotomae strain 5K33 can be used to over-
express homologous Brucella proteins [35]. Recombinant
B. neotomae strains overexpressing SOD and/or BP26
were found to induce protection against challenge with
virulent B. abortus 2308, B. melitensis 16 M, and B. suis
1330 [35]. However, the approach of overexpression of
protective antigen does not guarantee enhanced protec-
tion. For example, RB51leuB/SOD or RB51leuB/SOD/L7/
L12 does not provide statistically better protection than
RB51leuB when BALB/c mice were challenged with viru-
lent strain B. suis 1330 [27]. The addition of protective
antigen would seem to induce synergy and enhanced pro-
tection; however, one antigen may hinder the amount of
the other preventing sufficient presentation to the immune
system.
(2) Gene mutation
A virulence factor can be mutated in virulent pathogen,
leading to the possible generation of a live attenuated vac-
cine. Eighteen Brucella virulence factors have been
reported to be used for generation of live attenuated vac-
cines. These 18 virulence factors include: asp24, bp26,
exsA, manA, manB, mucR, omp25, omp31, p39, pgk, pgm,
purE, purK, virB2, vjbR, wbkA, wboA, and znuA. Among
these genes, manA and manB were mutated together in B.
abortus strain 2308 or B. melitensis strain 16M [36]. Two
other genes purE and purK were both mutated in B. meli-
tensis strain 16M [30]. The other 14 genes were mutated
individually in different parent Brucella strains. Most of
these mutants induced protection against virulent Brucella
challenge under different experimental conditions of the
mouse model. However, while RB51WboA provided pro-
tection in 11 case studies, RB51WboA failed to induce
protection against intranasal challenge with virulent
B. abortus challenge [19]. Therefore, a vaccine that works
out in one experimental condition may not work in
another experimental condition.
(3) Vaccine adjuvant
Live attenuated vaccines usually do not need any vaccine
adjuvant to boost the induction of antigen-specific
immune response. In total, 357 groups of vaccine experi-
ments did not use any vaccine adjuvant. Among them,
317 induced protection in the mouse model. However,
inactivated whole-organism vaccines may need to use
vaccine adjuvant to facilitate the induction of adaptive
immunity. IFA and oil adjuvants have been used in 5 and
12 groups of vaccine protection studies, respectively and
all of them induced protection. Among the six groups of
vaccine protection studies that used IL-12 as vaccine
adjuvants, only 3 (50%) of them demonstrated protection
[23,24]. IL-12 is an important cytokine for Th1 cell devel-
opment and proliferation and has exhibited an enhanced
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protective effect on Listeria and Leishmania infections
but it appears that in the context of Brucella, exogenous
IL-12 is indispensable. Statistically, the addition of an
adjuvant to a vaccine does not affect the efficacy of a vac-
cine (Table 1). However, since almost all vaccines that
were examined did not include an adjuvant, the data
might well be skewed.
(4) Vaccine viability
Whole-organism Brucella vaccines and vaccine candi-
dates are live attenuated, irradiated, or killed by heat or
chemicals. Live virulent Brucella strains cannot be used
as vaccines since they are not safe. Irradiated and killed
vaccines are both classified as inactivated vaccine type. In
our annotated data record, there exist 357 experimental
groups that use live attenuated vaccines, making up
nearly the entire amount of vaccines. Among them, 318
induced protection against virulent Brucella infection in
corresponding vaccine protection studies. Eleven out of
16 irradiated vaccines provided protection in the mouse
model. Only two out of 36 killed Brucella vaccine candi-
dates failed to generate protection. This does not mean
that killed vaccines are more effective than live attenu-
ated vaccines. Instead, the data suggest that killed Bru-
cella vaccine candidates can be protective giving the
appropriate vaccine formula (e.g., having adjuvants) and
experimental conditions.
(5) Mouse sex
The female sex was virtually the only sex used in the stu-
dies. There has not been a single group of vaccine protec-
tion that specifically claimed to use male mice. Only two
mouse groups used both female and male mice [37].
Therefore, the data is not sufficient to support that
mouse sex does not change the results.
(6) Mouse age at vaccination
Similar percent significances between the <69 day and
the 69-224 day-old mice were identified. Specifically,
90.6% of groups (289 out of 319) of vaccine protection
studies used mice under < 69 days old. In comparison,
80% of groups (48 out of 60) used mice with 69-226 days
old. The difference between these two groups was not
significantly different.
(7) Mouse sample size per experimental group
In our record, 3-134 mice per experimental group were
used in various studies. The most frequently used sample
size is 5 mice per group, accounting for 214 experimental
group studies. Among these groups, 26 groups did not
result in any protective response (P-value > 0.05).
(8) Vaccination frequency
In our records, a Brucella vaccine or vaccine candidate
was used in vaccination for once, twice, or three times.
This means that the variable “Vaccine Frequency” has
three values: 1, 2, or 3. It appears intuitive that the
greater the number of injections of the vaccine, the more
effective the vaccine is. However, based on the present
analysis, one vaccination is the most efficient frequency
of vaccination. This is because one vaccination with a live
attenuated Brucella vaccine (e.g., RB51 or S19) is suffi-
cient to induce significant protection in mouse models.
Killed Brucella vaccine candidates tend not to induce
protection in mice. The usage of two or three vaccina-
tions is often required for those inactivated vaccine can-
didates or those live attenuated vaccines that were
administrated differently (e.g., PO administration instead
of traditional IP injection). The frequency of 1 occurred
for 351 groups, 90% of which showed significant protec-
tion. When a vaccine was used twice, 79.2% of cases
showed significant protection. Lastly, when a vaccine was
used three times, 100% of protection was obtained.
(9) Vaccination-challenge interval
Different vaccination-challenge intervals have been
applied, ranging from 7 days to 210 days. The top three
vaccination-challenge intervals are 30 days (44 cases), 42
days (53 cases), and 56 days (64 cases). Among these inter-
vals, 75% to 93% of vaccine protection cases provided
significant protection. Our results showed that the vacci-
nation-challenge interval is not statistically significant fac-
tor for the vaccine protection efficacy outcome. This result
allows us to comfortably rearrange our experimental
design in terms of vaccination-challenge intervals.
(10) Challenge dose
The challenge doses used in most vaccine protection stu-
dies ranged from 104 to 106. Specifically, 247, 75, and 25
vaccine studies used challenge doses with the scale of
104, 105, and 106, respectively. Correspondingly, 212, 71,
and 22 groups induced protection, respectively. It
appears that the results of protections did not change
much in these groups. A higher amount of virulent chal-
lenge dose turned to increase the amount of Brucella
remaining in the spleen (i.e., CFU in the spleen). How-
ever, a higher CFU does not equal to a higher CFU
reduction. The reduction of CFUs in spleen is a factor
better correlated with protection efficacy than the absolu-
tion number of CFUs in spleen.
Discussion
Large amounts of literature data have been accumulated
in almost every biomedical domain. It is difficult to have
a comprehensive understanding of a research domain
without taking into account all possible data available in
the literature. Our study proves that meta-analysis is a
valid approach to study biomedical problems. New
knowledge and novel hypotheses may be generated from
the study of literature reports. It is frequent that we
could not find out the exact values for many variables
from many literature reports. This prevents us from
including many papers in our study. Therefore, it is cri-
tical for the authors of literature papers to describe
experimental design and protocols in details.
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Even for known Brucella vaccines (e.g., RB51), proper
experimental design for a vaccine protection study is
important to generate protection (except for testing dif-
ferent experimental conditions). Inhalation of aeroso-
lized Brucella is one of the major routes of disease
transmission in humans [16]. Therefore, to successfully
control brucellosis, it is crucial to identify those experi-
mental factors that may influence vaccine protection.
There are some variables which are not critical and
some variations are fine and do not affect the final pro-
tection outcome. However, to claim they are insignificant
is relative to the data collected from this study. For many
variables (e.g., Mouse Sex), the data presented are biased
and often insufficient to draw a conclusion. To overcome
this obstacle, we can include more datasets that cover
these other factors and try to have similar or balanced
numbers for different factors.
This study also suggests new foci for further research
into the protective mechanisms against Brucella. Many
hypotheses can be generated from the meta-analysis. For
example, most of the studies using an aerosol challenge
used the IN vaccination route. However, IN vaccination
route may not be the most effective way to induce protec-
tion against aerosol pathogen challenge. This is indicated
by the low rate of success from previous reports. However,
it has been found many times that systematic immuniza-
tion, including IP and IN immunization, may induce
strong protection against respiratory infection of virulent
Brucella. More evidences can be found from non-whole-
organism Brucella vaccine studies. For example, IN immu-
nization of mice with a B. melitensis lipopolysaccharide
subunit vaccine provided significant protection against dis-
seminated infection of the spleen and liver but SC immu-
nization of mice with the vaccine conferred significant
protection against infection of the spleen, liver, and lungs
[38]. The reasons of this phenomenon may be complex.
The mucus acts as a “physical barrier” as a means for pre-
venting foreign materials to enter the host body. One pos-
sible explanation is that Brucella vaccines may not
effectively penetrate into mucosal physical barriers (e.g.,
nose). Therefore, Brucella antigens cannot efficiently be
presented to the antigen presenting cells, including dendri-
tic cells and macrophages [39].
Meta-analysis is data analysis method applied to sum-
marizing research findings of individual studies at both
quantitative and qualitative levels [40]. Meta-analysis com-
bines several studies and thus is less influenced by local
findings from single studies. Meta-analysis can be used to
show whether the results are more varied than what is
expected from the sample diversity. Statistical testing of
overall factors and effect size parameters in related studies
can be performed using meta-analysis. Meta-analysis is
able to control for between-study variation; Moderators
can be included in meta-analysis to explain variation.
Meta-analysis has higher statistical power to detect an
effect than single studies with “n = 1 sized study sample”.
Meta-analysis can also be used to address information
overload since the high number of articles has been pub-
lished each year. Besides ANOVA, there are many differ-
ent statistical methods for meta-analysis [41-43]. ANOVA
is used in this study because it is relatively simple and fits
in with our research objectives.
The whole process of meta-analysis design and data
annotation is very time-consuming. It would be beneficial
to generate a general systematic meta-analysis design pat-
tern and develop advanced tools to implement biomedi-
cal meta-analysis more effectively. Recently we have
initiated the development of community-driven Vaccine
Ontology (VO; http://www.violinet.org/vaccineontology)
[10-12]. VO is a controlled vocabulary of terms and rela-
tions that pertains to the vaccine domain. While see-
mingly straightforward, the standardization of vaccine-
associated terms and the relations between these terms
requires multi-field knowledge and expertise on many
different levels. The Vaccine Ontology (VO), combined
with other sister ontologies (e.g., the Ontology for Biome-
dical Investigations or OBI), can be used to represent the
diverse variables used in analysis of animal responses to
vaccination (Figure 1). Not only these representations
can be understood by humans, but they can also be
parseable and understood by computers. Therefore, new
tools can be developed to understand and analyze the
collected literature data, thereby allowing “computer-
assisted automated reasoning”. For example, advanced
ontology-based literature mining tools may be developed
to automate many processes of retrieving and analyzing
data from the literature. Novel hypotheses may also be
generated to provide new avenues for future research.
These activities will increase the effectiveness of meta-
analysis of different variables to uncover those important
to vaccine-induced protection studies or other biomedi-
cal domains [44].
Our approach represents a genetic literature-based
meta-analysis of biological experiments in the vaccine pro-
tection investigation. Through meta-analysis we were able
to identify variables that significantly contributed to Bru-
cella vaccine protection. The method reported in this
study can be applied to analyze variables critical for vac-
cine protection against other infectious diseases (e.g.,
AIDS, malaria, and tuberculosis). Approximately 3,000
vaccines and the data of protection studies involving them
have been manually curated and stored in the Vaccine
Investigation and Online Information Network (VIOLIN)
vaccine database system [45]. This approach can also be
applied to study other pathogen-vaccine interactions in
specific animal models, as outlined in VIOLIN.
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Conclusions
A known vaccine may not induce protection if experimen-
tal conditions are not optimized. Our studies identified
several variables that play critical roles in inducing protec-
tive immunity in the mouse model, and many other vari-
ables do not. New knowledge and hypotheses were
obtained. For example, B. abortus cattle vaccine RB51 may
not induce protection in mice if the values of many experi-
mental variables (e.g., vaccination route, vaccine viability,
and challenge pathogen strain) change. Our study found
that IN or PO immunization tends to induce low protec-
tion, while IP or SC injection may induce systemic
immune response and protect against aerosol or IN patho-
gen challenge. The meta-analysis provides a unique sys-
tematic approach towards better understanding of
vaccine-induced protection to brucellosis.
Methods
Curation process of vaccine animal response data
As of December 12, 2011, 124 papers were identified
through a PubMed search for “Brucella vaccine mice
challenge”. These peer-reviewed research papers were
manually curated to identify variables and extract values
taken by these variables potentially important for vaccine
protection efficacy investigation.
Data transformation
The following six variables kept the continuous values:
vaccine dose, challenge pathogen dose, vaccination-chal-
lenge interval, challenge-killing interval, CFUs, CFU
reduction. Among them, vaccination-challenge interval
uses the unit of day, and log10 transformation was
applied for the other four variables. Other than these five
variables, the raw data of 14 other variables in the
Brucella vaccine protection meta-analysis was trans-
formed to discretized data using a data discretization
process. For example, the variable “Mouse Sex” has two
values: female and male. During the data discretization
step, the number string values, female and male, were
discretized to two discrete digital values 0 and 1,
respectively.
General data analysis
Microsoft Excel program was used for generating 2D plot
figures. Microsoft Excel was also used to calculate the
sums, averages, and standard deviations for this meta-
analysis.
ANOVA statistical analysis of Brucella vaccine
protection results
The analysis of variance (ANOVA) was first used to
analyze which variables contributed significantly to the
Brucella protection efficacy. R program was used to
implement ANOVA analysis of the transformed data
described above. Specifically, ANOVA for linear model fits
was used. The predictive model is “Protection-level ~.”
indicating we are testing how each other variable affects
the protection level. This linear model representation can
be understood and processed by statistical software pro-
grams such as R programming.
Additional material
Additional file 1: The curated data used for meta-analysis.
Additional file 2: The references of peer-reviewed journal papers
that were used for collecting data in the meta-analysis study.
List of abbreviations used
ANOVA: analysis of variance; ID: Intradermal route; IN: Intranasal route; IP:
Intraperitoneal route; IV: Intravenous route; PO: Per oral (or Per os) route; SC:
Subcutaneous route; VIOLIN: the Violin Investigation and OnLine Information
Network; VO: Vaccine Ontology.
Authors’ contributions
TT: Project design, literature data annotation, data analysis, and manuscript
drafting. OT: Literature data annotation and data analysis. YL, SS, and DNB:
Literature data annotation. ZX: Statistics data analyses. YH: Project design
and management, data interpretation, and manuscript drafting.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This project was supported by a NIH-NIAID grant (R01AI081062) and a
NIH-T32 training grant (RR007008-30).
Declarations
This article has been published as part of BMC Bioinformatics Volume 14
Supplement 6, 2013: Selected articles from the 10th International Conference
on Artificial Immune Systems (ICARIS). The full contents of the supplement
are available online at http://www.biomedcentral.com/bmcbioinformatics/
supplements/14/S6.
Author details
1Unit for Laboratory Animal Medicine, University of Michigan Medical School,
Ann Arbor, MI 48109, USA. 2Division of Comparative Medicine, University of
South Florida, Tampa, FL 33612, USA. 3Department of Biology, Eastern
Michigan University, Ypsilanti, MI 48197, USA. 4Department of Microbiology
and Immunology, University of Michigan Medical School, Ann Arbor, MI
48109, USA. 5Center for Computational Medicine and Bioinformatics,
University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Published: 17 April 2013
References
1. Glass GV: Primary, secondary, and meta-analysis of research. Educational
Research 1976, 5:3-8.
2. Lean IJ, Rabiee AR, Duffield TF, Dohoo IR: Invited review: Use of meta-
analysis in animal health and reproduction: methods and applications.
J Dairy Sci 2009, 92(8):3545-3565.
3. Altman DG: Statistics in medical journals: some recent trends. Stat Med
2000, 19(23):3275-3289.
4. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV: The new
global map of human brucellosis. Lancet Infect Dis 2006, 6(2):91-99.
5. Hilleman MR: Vaccines in historic evolution and perspective: a narrative
of vaccine discoveries. Vaccine 2000, 18(15):1436-1447.
Todd et al. BMC Bioinformatics 2013, 14(Suppl 6):S3
http://www.biomedcentral.com/1471-2105/14/S6/S3
Page 12 of 13
6. He Y, Vemulapalli R, Zeytun A, Schurig GG: Induction of specific cytotoxic
lymphocytes in mice vaccinated with Brucella abortus RB51. Infect Immun
2001, 69(9):5502-5508.
7. Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC:
Brucellosis: the case for live, attenuated vaccines. Vaccine 2009,
27(Suppl 4):D40-43.
8. Tamura S, Hasegawa H, Kurata T: Estimation of the effective doses of
nasal-inactivated influenza vaccine in humans from mouse-model
experiments. Jpn J Infect Dis 2010, 63(1):8-15.
9. Brinkman RR, Courtot M, Derom D, Fostel J, He Y, Lord P, Malone J,
Parkinson H, Peters B, Rocca-Serra P, et al: Modeling biomedical
experimental processes with OBI. Journal of Biomedical Semantics 2010,
Accepted.
10. He Y, Cowell L, Diehl AD, Mobley HL, Peters B, Ruttenberg A,
Scheuermann RH, Brinkman RR, Courtot M, Mungall C, et al: VO: Vaccine
Ontology. The 1st International Conference on Biomedical Ontology (ICBO
2009) Nature Precedings Buffalo, NY, USA; 2009, http://precedings.nature.
com/documents/3553/version/1 July 24-26, 2009.
11. He Y, Xiang Z: Bioinformatics analysis of Brucella vaccines and vaccine
targets using VIOLIN. In Immunome Res. Volume 6. Suppl 1; 2010:S5.
12. Hur J, Xiang Z, Feldman EL, He Y: Ontology-based Brucella vaccine
literature indexing and systematic analysis of gene-vaccine association
network. BMC Immunol 2011, 12:49.
13. He Y, Xiang Z, Todd T, Courtot M, Brinkman RR, Zheng J, Stoeckert CJ Jr,
Malone J, Rocca-Serra P, Sansone SA, et al: Ontology representation and
ANOVA analysis of vaccine protection investigation. Bio-Ontologies 2010:
Semantic Applications in Life Sciences, 18th Annual International Conference
on Intelligent Systems for Molecular Biology (ISMB): 2010; Boston, MA, USA.
July 11-13 2010, 4-page full paper (Accepted).
14. Dougan G: Vaccines: whole organism. Wiley Online Library 2001, 1-5
[http://onlinelibrary.wiley.com/doi/10.1038/npg.els.0000491/pdf].
15. Sayers S, Ulysse G, Xiang Z, He Y: Vaxjo: a web-based vaccine adjuvant
database and its application for analysis of vaccine adjuvants and their
uses in vaccine development. J Biomed Biotechnol 2012, 2012:831486.
16. Schurig GG, Roop RMd, Bagchi T, Boyle S, Buhrman D, Sriranganathan N:
Biological properties of RB51; a stable rough strain of Brucella abortus.
Vet Microbiol 1991, 28(2):171-188.
17. Silva TM, Costa EA, Paixao TA, Tsolis RM, Santos RL: Laboratory animal
models for brucellosis research. J Biomed Biotechnol 2011, 2011:518323.
18. Stevens MG, Olsen SC, Palmer MV, Pugh GW Jr: Immune responses and
resistance to brucellosis in mice vaccinated orally with Brucella abortus
RB51. Infect Immun 1996, 64(11):4534-4541.
19. Surendran N, Sriranganathan N, Lawler H, Boyle SM, Hiltbold EM, Heid B,
Zimmerman K, Witonsky SG: Efficacy of vaccination strategies against
intranasal challenge with Brucella abortus in BALB/c mice. Vaccine 2011,
29(15):2749-2755.
20. Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F: Brucella abortus
RB51 induces protection in mice orally infected with the virulent strain
B. abortus 2308. Infect Immun 2003, 71(5):2326-2330.
21. Monreal D, Grillo MJ, Gonzalez D, Marin CM, De Miguel MJ, Lopez-Goni I,
Blasco JM, Cloeckaert A, Moriyon I: Characterization of Brucella abortus
O-polysaccharide and core lipopolysaccharide mutants and
demonstration that a complete core is required for rough vaccines to
be efficient against Brucella abortus and Brucella ovis in the mouse
model. Infect Immun 2003, 71(6):3261-3271.
22. Sanakkayala N, Sokolovska A, Gulani J, Hogenesch H, Sriranganathan N,
Boyle SM, Schurig GG, Vemulapalli R: Induction of antigen-specific
Th1-type immune responses by gamma-irradiated recombinant Brucella
abortus RB51. Clin Diagn Lab Immunol 2005, 12(12):1429-1436.
23. Lee IK, Olsen SC, Bolin CA: Effects of exogenous recombinant interleukin-
12 on immune responses and protection against Brucella abortus in a
murine model. Can J Vet Res 2001, 65(4):223-228.
24. Lee IK, Olsen SC, Kehrli M, Bolin CA: The adjuvant effect of a single dose
of interleukin-12 on murine immune responses to live or killed Brucella
abortus strain RB51. Can J Vet Res 1999, 63(4):284-287.
25. Olsen SC, Waters WR, Stoffregen WS: An aerosolized Brucella spp.
challenge model for laboratory animals. Zoonoses Public Health 2007,
54(8):281-285.
26. Edmonds MD, Cloeckaert A, Elzer PH: Brucella species lacking the major
outer membrane protein Omp25 are attenuated in mice and protect
against Brucella melitensis and Brucella ovis. Vet Microbiol 2002,
88(3):205-221.
27. Rajasekaran P, Surendran N, Seleem MN, Sriranganathan N, Schurig GG,
Boyle SM: Over-expression of homologous antigens in a leucine
auxotroph of Brucella abortus strain RB51 protects mice against a
virulent B. suis challenge. Vaccine 2011, 29(17):3106-3110.
28. Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA: Aerosol infection of
BALB/c mice with Brucella melitensis and Brucella abortus and protective
efficacy against aerosol challenge. Infect Immun 2007, 75(10):4923-4932.
29. Montaraz JA, Winter AJ: Comparison of living and nonliving vaccines for
Brucella abortus in BALB/c mice. Infect Immun 1986, 53(2):245-251.
30. Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL: Oral
vaccination with Brucella melitensis WR201 protects mice against
intranasal challenge with virulent Brucella melitensis 16M. Infect Immun
2004, 72(7):4031-4039.
31. Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG:
Overexpression of protective antigen as a novel approach to enhance
vaccine efficacy of Brucella abortus strain RB51. Infect Immun 2000,
68(6):3286-3289.
32. Vemulapalli R, He Y, Sriranganathan N, Boyle SM, Schurig GG: Brucella
abortus RB51: enhancing vaccine efficacy and developing multivalent
vaccines. Vet Microbiol 2002, 90(1-4):521-532.
33. Vemulapalli R, He Y, Buccolo LS, Boyle SM, Sriranganathan N, Schurig GG:
Complementation of Brucella abortus RB51 with a functional wboA gene
results in O-antigen synthesis and enhanced vaccine efficacy but no
change in rough phenotype and attenuation. Infect Immun 2000,
68(7):3927-3932.
34. Rajasekaran P, Seleem MN, Contreras A, Purwantini E, Schurig GG,
Sriranganathan N, Boyle SM: Brucella abortus strain RB51 leucine
auxotroph as an environmentally safe vaccine for plasmid maintenance
and antigen overexpression. Appl Environ Microbiol 2008, 74(22):7051-7055.
35. Moustafa D, Garg VK, Jain N, Sriranganathan N, Vemulapalli R:
Immunization of mice with gamma-irradiated Brucella neotomae and its
recombinant strains induces protection against virulent B. abortus, B.
melitensis, and B. suis challenge. Vaccine 2011, 29(4):784-794.
36. Kahl-McDonagh MM, Ficht TA: Evaluation of protection afforded by
Brucella abortus and Brucella melitensis unmarked deletion mutants
exhibiting different rates of clearance in BALB/c mice. Infect Immun 2006,
74(7):4048-4057.
37. Corbel MJ: The immunogenic activity of ribosomal fractions derived from
Brucella abortus. J Hyg (Lond) 1976, 76(1):65-74.
38. Bhattacharjee AK, Izadjoo MJ, Zollinger WD, Nikolich MP, Hoover DL:
Comparison of protective efficacy of subcutaneous versus intranasal
immunization of mice with a Brucella melitensis lipopolysaccharide
subunit vaccine. Infect Immun 2006, 74(10):5820-5825.
39. Zhu J, Larson CB, Ramaker MA, Quandt K, Wendte J, Ku K, Chen F,
Jourdian G, Vemulapalli R, Schurig GG, et al: Characterization of
recombinant B. abortus strain RB51SOD towards understanding the
uncorrelated innate and adaptive immune responses induced by
RB51SOD compared to its parent vaccine strain RB51. Frontiers in Cellular
and Infection Microbiology 2012.
40. Beard MT, Curry EL, Edwards K, Adams BN: Advances in meta-analysis as a
research method. ABNF J 1997, 8(5):92-97.
41. Hedges LV, Olkin I: Statistical methods for meta-analysis New York: Academic
Press, Inc; 1985.
42. Cooper H, Hedges LV, (eds): The handbook of research synthesis and meta-
analysis. 2 edition. New York: Russell Sage Foundation; 2009.
43. van Houwelingen HC, Arends LR, Stijnen T: Advanced methods in meta-
analysis: multivariate approach and meta-regression. Stat Med 2002,
21(4):589-624.
44. Consortium O: The modeling of biomedical experimental processes with
OBI. In Bio-Ontolgies Workshop (at ISMB 2009) June 27 - July 2, 2009. Volume
2009. Stockholm, Sweden; 2009:1-4.
45. Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y,
Olenzek EA, Zhao B, et al: VIOLIN: vaccine investigation and online
information network. Nucleic Acids Res 2008, , 36 Database: D923-928.
doi:10.1186/1471-2105-14-S6-S3
Cite this article as: Todd et al.: Meta-analysis of variables affecting
mouse protection efficacy of whole organism Brucella vaccines and
vaccine candidates. BMC Bioinformatics 2013 14(Suppl 6):S3.
Todd et al. BMC Bioinformatics 2013, 14(Suppl 6):S3
http://www.biomedcentral.com/1471-2105/14/S6/S3
Page 13 of 13
